U-Medico provides analytical and formulation development services based on its extensive knowledge and technology in protein physicochemical characterization. Our target modalities are diverse, covering biopharmaceuticals such as antibody drugs and fusion proteins, gene and cellular therapeutics such as adeno-associated virus (AAV) vectors, lentiviruses, and tumor-associated viruses, and even lipid nanoparticles (LNPs) for RNA delivery. Our laboratories are equipped with BSL2 and P2 level facilities.
Characterization Services
Analytical Ultracentrifugation（AUC）is one of U-Medico's core expertise. Under the guidance of Professor Susumu Uchiyama of Osaka University, our CSO and a leading expert in AUC, we have been providing world-class AUC services for over 15 years since 2009.
-
Peptide Mapping ： Analysis of protein sequences and post-translational modifications
-
Intact Mass Analysis ：
-
Native MS ： Analyze the mass of protein complexes while maintaining non-covalent binding
-
HDX-MS ： Methods to reveal protein conformational changes and interaction sites
U-Medico is one of the few providers of hydrogen deuterium exchange mass spectrometry (HDX-MS) services in the world, having performed more than 40 projects since its launch in 2013, characterized by very high sequence coverage (typically >90%).
In particle and aggregate analysis, we have the technology and experience to analyze particles ranging from nano to micron size from multiple angles, enabling us to meet a wide range of needs.
Formulation Development Services
U-Medico conducts formulation development for liquid pharmaceutical products. In addition to formulation and container selection, we also evaluate formulation stability and the impact of container closure systems on pharmaceutical products.
Quality Testing Services
We will provide comprehensive analytical services, focusing on viral vectors for gene therapy. In addition, we plan to start quality testing services in 2025 in compliance with GMP standards.
Manufacturing Services
Based on our extensive analytical knowledge and experience, we provide high quality manufacturing services, and in 2025 we plan to begin reference product manufacturing and process development of AAV vectors for analytical method development.
OUR MISSION
We contribute to global healthcare by utilizing the world's most advanced science and technology.
We are well versed in the solution properties of proteins, nucleic acids, and other biopolymers that make up biopharmaceuticals, and we aim to use our advanced technology and expertise to contribute to the improvement of human health and welfare.
OUR VISION
We support the pharmaceutical industry by implementing the world's most advanced science and technology into society and supporting the manufacture of cutting-edge biopharmaceuticals.
Pharmaceutical production of advanced biopharmaceuticals involves many challenges that are difficult to solve with existing pharmaceutical technologies and experience. At the same time, cutting-edge research is being conducted daily at universities. Through our collaboration with Osaka University, we support the production of safe pharmaceuticals by implementing these scientific technologies in society and solving issues in pharmaceuticals.
U-Medico Inc.
CEO
Ayano Fukuhara, Ph.D.
U-Medico Inc. is a CRO providing analytical and research services that was spun out from Osaka University in 2006. The company provides high-quality analysis and formulation formulation development for biopharmaceuticals and gene therapeutics, including antibodies and fusion proteins, and serves more than 40 domestic and foreign clients each year. We contribute to safe and reliable drug development through comprehensive support from new drug development to manufacturing and approval.
Our strength lies in our unique know-how, built on world-leading analytical technologies and extensive experience. Especially in biophysical characterization such as ultracentrifugal analysis (AUC), hydrogen deuterium exchange mass spectrometry (HDX-MS), and particle/aggregate analysis, we provide highly accurate and unique approaches, contributing significantly to solving our clients' pharmaceutical manufacturing challenges. In formulation development services, we support the creation of more stable drug formulations through the selection of containers and formulations, stability testing, and more.
Furthermore, u-medico has started full-scale analytical services for gene cell therapy in 2022. Gene therapy to fundamentally treat genetic diseases has been attracting attention in recent years, and we are providing world-class analysis and quality testing services to realize stable production. 2024 will also see the launch of manufacturing services for gene therapy viral vectors, supporting stable product development for our clients. We will also start production of viral vectors for gene therapy in 2024 to support stable product development for our clients.
Our goal is to build a future in which Japan leads the world in biopharmaceuticals and gene therapeutics. We will continue to be your partner in drug development as an analyst, researcher, and consultant who sincerely listens to your needs and proposes the best solutions. We hope you will make use of our knowledge and experience in your business.
CEO Ph.D. (Applied Life Sciences), MBA Ayano Fukuhara |
Founder, CSO Ph.D. (Pharmacy) Susumu Uchiyama |
COO Master of Business Administration(Professional) Akira Kawai |
Executive Officer and General Manager, Analytical Business Headquarters Ph.D. (Engineering) Takaaki Kurinomaru |
Executive Officer and General Manager, Manufacturing Division Ph.D. (Life Sciences), Patent Attorney Mitsuko Fukuhara |
| Company Name | U-Medico Inc. |
|---|---|
| Address |
【Analytical Center】 7F Erimo Building 2-1-1 Senbanishi, Minoh, Osaka, 562-0036 Japan 【Manufacturing Center】 502 Photonics Center, Osaka University 2-1 Yamadaoka, Suita, Osaka, 565-0871 Japan |
| TEL | +81-6-6155-7835 |
| info@u-medico.co.jp | |
| Representative | CEO Ayano Fukuhara, Ph.D. |
| Establishment | August 2006 |
| 2006 |
Established U-Medico Inc. 
|
|---|---|
| 2009 |
Start of ultracentrifugal analysis (AUC) service Providing services with a focus on biopharmaceuticals |
| 2013 |
Start of Hydrogen Deuterium Exchange Mass Spectrometry (HDX-MS) service
|
| 2015 |
Start of particle analysis service Launch of formulation development services |
| 2016 |
Start of AUC service for gene therapy viral vectors
|
| 2019 |
Participated in the research and development project “Development of New Mass Production Technology for Vectors for Gene and Cell Therapy” of the Japan Agency for Medical Research and Development (AMED)
|
| 2021 |
Partnership with Coriolis Pharma, headquartered in Germany
|
| 2022 |
Mass spectrometry service for viral vectors is launched Renewal of company logo Started BSL2 service 
|
| 2024 |
Participated in AMED's R&D project “Integrated Development of Viral Vector Manufacturing Technology“ Participated in AMED's R&D project “Production of High-Quality Gene Therapy Vectors for FIH Testing“ First Capital and Business Alliance Shimadzu Corporation, AZWAN Corporation |
| 2025 |
Head office to be relocated to Minoh Senba Plans to launch GMP analysis facility |
We offer world-class ultracentrifugal analysis services.
Researchers with expertise in engineering, biochemistry, virology, etc.
We have published more than 30 papers in original or collaborative research. We also actively disseminate information at domestic and international conferences and seminars.
Tailor-made services to meet your needs.
Sharing the latest information and providing solutions to problems in biopharmaceutical formulation development.
We have provided analytical services to almost all of Japan's top 10 pharmaceutical companies.
Laboratory of Macromolecular Biotechnology (Uchiyama Laboratory)
Department of biotechnology, Graduate School of Engineering Osaka University
Many foods and pharmaceuticals are made using biotechnology. In Uchiyama Laboratory, the goal is to understand the physical properties, structures, and functions of solutions and gels of proteins, nucleic acids, polysaccharides, and other biological "macromolecules" that constitute foods, gene therapy vectors, and biopharmaceuticals, and to contribute to the production of high-quality and safe foods and pharmaceuticals.
Find out more under www.macromolecularbiotechnology.com
Through our collaboration with Osaka University, we conduct research on physical properties for the development of high-quality biopharmaceuticals. We also develop technologies for analysis and quality control of therapeutic viral vectors.
Coriolis Pharma
Coriolis Pharma is a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs including proteins, peptides, monoclonal antibodies, nucleic acids, virus-like particles, vaccines, advance therapy medicinal products (ATMPs) and genetically modified organisms (GMOs). Coriolis Pharma offers integrated development services for liquid and lyophilized formulations with all required technologies and analytical methods available in house. For each individual project, highly skilled scientists develop tailor-made study designs that align with the clients’ drug development strategy. With science-driven innovative solutions, Coriolis Pharma supports all phases of drug development including troubleshooting, batch-release testing including innovative methods and formulation optimization even beyond market approval. Coriolis’s mission is: formulating innovation!
Find out more under www.coriolis-pharma.com
Through our collaboration with Coriolis Pharma, we aim to provide innovative formulation development services for biopharmaceuticals and new modalities.
Shimadzu Corporation
Founded in 1875, Minebea is a precision instrument manufacturer involved in analytical and measuring instruments, diagnostic imaging equipment, industrial machinery, and aeronautical equipment. The company is known for its innovation and high quality in research and development, especially in the fields of analytical and diagnostic imaging instruments, for which it enjoys a high reputation worldwide. Based on its corporate motto, “Contribute to society through science and technology,” and management philosophy, “Fulfill our aspirations for the health of people and the planet,” the company contributes to the advancement of medicine and the promotion of health.
Find out more under https://www.shimadzu.co.jp/
Through collaboration with Shimadzu, we will develop applications such as liquid chromatography and mass spectrometry and promote their overseas development.
AS ONE Corporation
As a general wholesaler and trading company of scientific instruments and industrial and medical equipment, AZWAN Corporation continues to grow together with Japanese science and technology. Under our management philosophy of “Innovation and Creation,” we continue to provide products and services that meet customer needs and constantly challenge ourselves to create new value. We also seek to improve customer satisfaction by integrating virtual catalogs and realistic logistics with advanced information systems.
Find out more under https://www.as-1.co.jp/
In cooperation with As One, we will accelerate customer development through overseas sales channels including Japan and Asia.
【Analytical Center】
7F Erimo Building
2-1-1 Senbanishi, Minoh,
Osaka, 562-0036 Japan
【Manufacturing Center】
502 Photonics Center, Osaka University
2-1 Yamadaoka, Suita,
Osaka, 565-0871 Japan